

## EXECUTIVE REMUNERATION REVIEW

**24 January 2023: Melbourne, Australia.**

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), (**Rhinomed** or **Company**) a leader in wearable nasal and respiratory technology, advises that after an external benchmarking process its Board has resolved to change the fixed remuneration for the Company's Managing Director and Chief Executive Officer, Mr. Michael Johnson.

The Board last approved a change to Michael Johnson's fixed remuneration on 1 March 2018. The changes will take effect from 1 July 2022 and Mr. Johnson will be back paid on the next payroll run.

The key terms and conditions of Mr. Johnson's approved remuneration structure are outlined below;

<b>Effective date:</b>	1 July 2022
<b>Total fixed remuneration:</b>	\$375,000 per annum inclusive of statutory superannuation.
<b>Short term incentive:</b>	Potential per annum for the award of up to a maximum of \$150,000, inclusive of statutory superannuation, subject to Board approval on the achievement of the following targets; <ul style="list-style-type: none"><li>• Financial and distribution targets – 60% weighting</li><li>• Product innovation – 10% weighting</li><li>• Business development – 25% weighting</li><li>• Operations – 5% weighting</li></ul>

All other terms and condition remain unchanged.

This report has been authorised for release to the market by the Board.

<b>Company</b>	<b>Investor and Media Relations</b>
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 <a href="mailto:mjohnson@rhinomed.global">mjohnson@rhinomed.global</a> Follow us on <b>Twitter</b> @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a>

### **About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.